Us Bancorp \De\ Allakos Inc. Transaction History

Us Bancorp \De\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$3.6 - $5.25 $1,821 - $2,656	506 Added 49.56%	1,527 $6,000
Q1 2023 May 09, 2023	SELL	$4.3 - $8.27 $12,981 - $24,967	-3,019 Reduced 74.73%	1,021 $4,000
Q4 2022 Feb 13, 2023	BUY	$5.66 - $8.42 $6,469 - $9,624	1,143 Added 39.45%	4,040 $34,000
Q3 2022 Oct 27, 2022	BUY	$3.02 - $6.12 $8,748 - $17,729	2,897 New	2,897 $18,000
Q2 2022 Aug 01, 2022	SELL	$2.6 - $6.14 $4,726 - $11,162	-1,818 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$5.08 - $9.81 $8,483 - $16,382	1,670 Added 1128.38%	1,818 $10,000
Q4 2021 Feb 11, 2022	BUY	$8.55 - $111.89 $914 - $11,972	107 Added 260.98%	148 $1,000
Q3 2021 Nov 10, 2021	SELL	$76.53 - $110.43 $1,377 - $1,987	-18 Reduced 30.51%	41 $4,000
Q2 2021 Aug 05, 2021	SELL	$85.37 - $114.1 $341 - $456	-4 Reduced 6.35%	59 $5,000
Q4 2020 Feb 04, 2021	BUY	$79.58 - $152.45 $954 - $1,829	12 Added 23.53%	63 $9,000
Q3 2020 Nov 10, 2020	BUY	$66.43 - $90.99 $531 - $727	8 Added 18.6%	51 $4,000
Q2 2020 Aug 07, 2020	BUY	$44.04 - $80.69 $1,453 - $2,662	33 Added 330.0%	43 $3,000
Q1 2020 May 13, 2020	BUY	$44.49 - $93.39 $444 - $933	10 New	10 $0

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.